Candida | Aspergillus | Endemic Mycoses | Cryptococcus | Immunocompromised Hosts
- Candida is most common fungal cause of osteomyelitis - think IV drug users and vertebral involvement
- Tissue biopsy is ESSENTIAL for diagnosis - fungal cultures and special stains (GMS, PAS)
- 1,3-beta-D-glucan serum marker helpful but NOT specific for site of infection
- Prolonged antifungal therapy 6-12 months - much longer than bacterial osteomyelitis
- Surgical debridement often required - antifungals alone frequently insufficient
- “Fungal osteomyelitis has INDOLENT course - delayed diagnosis is common
- “Aspergillus in immunocompromised is aggressive and often fatal without early treatment
- “Coccidioides is endemic to southwestern USA - soil exposure history critical
- “Cryptococcus gattii can affect IMMUNOCOMPETENT patients in endemic regions
Consider fungal osteomyelitis if: immunocompromised patient (HIV, transplant, chemotherapy), culture-negative osteomyelitis not responding to antibiotics, IV drug user with vertebral infection, or endemic area travel history. Index of suspicion is key.
Tissue biopsy is ESSENTIAL - blood cultures rarely positive, 1,3-beta-D-glucan is nonspecific. Send for fungal stains (GMS, PAS), fungal culture (takes 4-6 weeks), and histopathology showing granulomatous inflammation with fungal elements.
6-12 months antifungal therapy - much longer than bacterial osteomyelitis. Choice depends on organism: fluconazole for Candida, voriconazole for Aspergillus, itraconazole for endemic mycoses. Surgical debridement often needed.
Cryptococcus gattii can cause osteomyelitis in immunocompetent hosts in endemic regions including Australia, the Pacific Northwest, and tropical Asia - unlike C. neoformans which affects the immunocompromised. Consider it in any patient with a lytic bone lesion mimicking tumour.
- Risk Factors
- IV drug use, TPN, central lines, neutropenia, diabetes
- Sites
- Vertebrae (most common), sternum, ribs
- Treatment
- Fluconazole 6-12 months; AmB if severe
- Prognosis
- Good if early diagnosis
- Risk Factors
- Neutropenia, transplant, steroids, CGD
- Sites
- Vertebrae, ribs, skull base
- Treatment
- Voriconazole first-line; surgery essential
- Prognosis
- Poor - high mortality
- Risk Factors
- Endemic SW USA, soil exposure, Filipino/African heritage
- Sites
- Vertebrae, pelvis, long bones, skull
- Treatment
- Fluconazole or itraconazole 12+ months
- Prognosis
- Chronic relapsing course
- Risk Factors
- Endemic Mississippi/Ohio River, soil/wood
- Sites
- Vertebrae, ribs, long bones
- Treatment
- Itraconazole; AmB for severe
- Prognosis
- Good with treatment
- Risk Factors
- Endemic Ohio/Mississippi Valley, bird/bat droppings
- Sites
- Vertebrae, ribs, long bones
- Treatment
- Itraconazole 12 months
- Prognosis
- Good with treatment
- Risk Factors
- HIV/AIDS (neoformans), immunocompetent hosts in endemic regions (gattii)
- Sites
- Vertebrae, skull, long bones
- Treatment
- Fluconazole long-term; AmB induction
- Prognosis
- Variable - depends on immune status
CANDID HOSTRisk Factors for Fungal Osteomyelitis
Hook:A CANDID HOST lets fungi in - immunocompromised patients are susceptible to fungal bone infection!
FAVIAntifungal Drug Selection
Hook:FAVI your treatment - choose the right antifungal based on the organism!
Overview and Epidemiology
Fungal osteomyelitis is rare but increasing with rising immunocompromised populations (HIV, transplant recipients, chemotherapy). The indolent course leads to delayed diagnosis. Examiners expect you to recognize risk factors, order appropriate investigations (tissue biopsy), and know prolonged treatment duration.
- Rare: Less than 1% of all osteomyelitis cases
- Increasing incidence: Rising immunocompromised population
- Candida most common: 40-60% of fungal osteomyelitis
- Mortality: Aspergillus 50-80%, others 10-20% with treatment
- Delayed diagnosis: Average 6 months symptom-to-diagnosis
- HIV/AIDS: CD4 less than 200 - Cryptococcus, Histoplasma
- Organ transplant: Aspergillus in first 6 months post-transplant
- Haematologic malignancy: Neutropenia - Aspergillus, Candida
- IV drug users: Candida vertebral osteomyelitis
- Diabetes mellitus: Candida, mucormycosis
Definition
Fungal osteomyelitis is bone infection caused by pathogenic fungi, typically occurring in immunocompromised hosts or following exposure to endemic fungi in specific geographic regions. The infection has an indolent course with nonspecific symptoms, leading to delayed diagnosis averaging 6 months.
Key Pathophysiology
Fungal pathogens reach bone through:
- Hematogenous spread - most common (Candida, Cryptococcus)
- Direct inoculation - trauma, surgery
- Contiguous spread - from adjacent soft tissue infection
Unlike bacterial osteomyelitis, fungal infections typically cause granulomatous inflammation with tissue destruction and minimal periosteal reaction on imaging.
Microbiology
Candida Species
- C. albicans most common (50-70% of cases)
- Other species: C. tropicalis, C. glabrata, C. parapsilosis
- Yeast form - oval budding cells
- Pseudohyphae - can form in tissue
- Normal commensal - becomes pathogenic when host defenses impaired
- Hematogenous spread from candidemia
- Vertebral osteomyelitis most common site
- IV drug users - lumbosacral spine, sternoclavicular joint
- TPN/central line patients - any bone
- Indolent course with back pain, low-grade fever
An IV drug user presenting with chronic back pain and low-grade fever should prompt consideration of Candida vertebral osteomyelitis. Blood cultures are only positive in 50% - tissue biopsy is essential. Treatment is fluconazole 400-800mg daily for 6-12 months.
Treatment
- Fluconazole 400-800mg daily - first-line for susceptible Candida
- Amphotericin B deoxycholate or liposomal - severe infection, azole resistance
- Echinocandins (caspofungin, micafungin) - alternative for azole-resistant species
- Duration: 6-12 months - longer than bacterial osteomyelitis
- Surgical debridement - recommended if abscess, instability, or poor response
Candida treatment is generally successful with appropriate antifungal therapy and debridement when indicated.
Clinical Presentation
Fungal osteomyelitis has an indolent, insidious course with nonspecific symptoms. Average time from symptom onset to diagnosis is 6 months. Think fungal when: culture-negative osteomyelitis, not responding to antibiotics, immunocompromised host, or endemic area exposure.
Clinical Features
- Pain - most common symptom (90%)
- Usually dull, aching, progressive
- May be present for weeks to months before diagnosis
- Swelling - variable, often minimal early
- Limited range of motion if near joint
- Low-grade fever - less than 38.5C (often absent)
- Night sweats - especially endemic mycoses
- Weight loss - chronic infection
- Malaise, fatigue
- High fever less common than bacterial osteomyelitis
Key Distinguishing Features
- Longer symptom duration before diagnosis than bacterial (months vs weeks)
- Less acute presentation - indolent course
- Lower inflammatory markers - CRP/ESR often only mildly elevated
- Poor response to antibiotics - key clue to fungal etiology
- Immunocompromised status - should prompt fungal workup
Symptoms vary by causative organism and immune status of the host.
Diagnosis
Blood cultures are often negative in fungal osteomyelitis. Serology and beta-D-glucan are nonspecific. Tissue biopsy with fungal stains and culture is ESSENTIAL for diagnosis. Do not delay biopsy - fungal cultures take 4-6 weeks.
Laboratory Investigations
- Findings
- Mildly to moderately elevated
- Utility
- Nonspecific - lower than bacterial osteomyelitis
- Findings
- Often normal or mildly elevated
- Utility
- May be low in neutropenic patients
- Findings
- Elevated in Candida, Aspergillus, Histoplasma
- Utility
- Nonspecific - does not identify site or organism
- Findings
- Elevated in Aspergillus
- Utility
- More specific for aspergillosis; serum and BAL
- Findings
- Positive in less than 50% of Candida cases
- Utility
- Often negative - not sufficient to rule out fungal infection
- Findings
- Gold standard - takes 4-6 weeks
- Utility
- Send for fungal culture specifically
- Findings
- Granulomatous inflammation, fungal elements
- Utility
- GMS and PAS stains essential
1,3-beta-D-glucan is a cell wall component of most pathogenic fungi (except Cryptococcus and Mucorales). It indicates fungal infection but does NOT identify the organism or site. Tissue diagnosis is still required. False positives occur with hemodialysis, certain antibiotics, and IVIG.
Tissue Biopsy - The Gold Standard
- CT-guided or open biopsy of affected bone
- Multiple samples (3 or more) increase yield
- Send for: fungal culture, bacterial culture, histopathology
- Special stains: GMS (Grocott methenamine silver), PAS (Periodic acid-Schiff)
- PCR - increasingly available for rapid identification
- Fungal cultures take 4-6 weeks - do not delay treatment if high suspicion
BIOPSYFungal Osteomyelitis Diagnosis
Hook:BIOPSY is the key - tissue diagnosis is ESSENTIAL for fungal osteomyelitis!
Management
Antifungal Drug Selection by Organism
- First-Line Agent
- Fluconazole 400-800mg daily
- Alternative
- Amphotericin B or echinocandin
- Duration
- 6-12 months
- First-Line Agent
- Echinocandin then oral azole
- Alternative
- Amphotericin B
- Duration
- 6-12 months
- First-Line Agent
- Voriconazole 6mg/kg then 4mg/kg BD
- Alternative
- Isavuconazole, liposomal AmB
- Duration
- 6-12 months minimum
- First-Line Agent
- Fluconazole 400-800mg daily
- Alternative
- Itraconazole, amphotericin B
- Duration
- 12+ months, may be lifelong
- First-Line Agent
- Itraconazole 200mg BD
- Alternative
- Amphotericin B for severe
- Duration
- 6-12 months
- First-Line Agent
- Itraconazole 200mg BD
- Alternative
- Amphotericin B for severe
- Duration
- 12 months
- First-Line Agent
- Fluconazole 400-800mg daily
- Alternative
- AmB + flucytosine induction
- Duration
- 6-12 months, secondary prophylaxis in HIV
Voriconazole is first-line for invasive aspergillosis including osteomyelitis. It has excellent bone penetration. Monitor liver function and visual symptoms. Drug-drug interactions are common - check all medications. Continue until immune reconstitution.
Key Principles
- Prolonged treatment - 6-12 months minimum (longer than bacterial)
- Source control - surgical debridement often required
- Treat underlying immunocompromise - improve host defenses
- Monitor drug levels - especially voriconazole, posaconazole
- Watch for toxicity - hepatic, renal, visual (voriconazole)
Duration should be individualized based on clinical and radiological response.
Mucormycosis - the Missing Angioinvasive Mould
The topic names mucormycosis twice - as a diabetic risk and as a beta-D-glucan-negative organism - but never develops this dangerous mould.
- Angioinvasive mould of the diabetic and immunosuppressed. Mucormycosis (Rhizopus, Mucor and related Mucorales) is angioinvasive like Aspergillus, causing vascular thrombosis and tissue infarction and necrosis (black eschar). The classic host is diabetes with ketoacidosis, plus neutropenia, transplant, and iron overload or deferoxamine; it reaches bone from rhino-orbital-cerebral disease (skull base, maxilla) or a contaminated wound.
- The biopsy looks different from Aspergillus. On histology Mucorales are broad, aseptate (or sparsely septate), ribbon-like hyphae with wide-angle branching - unlike the narrow, septate, acute-angle hyphae of Aspergillus. Crucially, beta-D-glucan and galactomannan are negative, so serology does not help and tissue is essential.
- Treatment is amphotericin plus urgent radical surgery - not voriconazole. First-line is liposomal amphotericin B with early, aggressive surgical debridement (the infarcted tissue is avascular, so drugs cannot reach it), reversal of the underlying state (correct ketoacidosis, reduce immunosuppression, stop deferoxamine), and isavuconazole or posaconazole as step-down or salvage. Mucorales are intrinsically resistant to voriconazole - so breakthrough mucormycosis can occur in a patient on voriconazole prophylaxis. Mortality is high.
Q: How does mucormycosis of bone differ from Aspergillus, and how is it treated?
A: Both are angioinvasive, but mucormycosis (Rhizopus/Mucor) classically affects diabetics in ketoacidosis (and neutropenic/transplant/iron-overload) and shows broad, aseptate, ribbon-like hyphae with wide-angle branching - versus Aspergillus's narrow septate acute-angle hyphae. Beta-D-glucan and galactomannan are negative for Mucorales (serology useless - biopsy essential). Treatment = liposomal amphotericin B + urgent aggressive surgical debridement (infarcted tissue is avascular) + reverse the underlying state (correct ketoacidosis, cut immunosuppression, stop deferoxamine) + isavuconazole/posaconazole step-down. Not voriconazole - Mucorales are intrinsically resistant (breakthrough occurs on voriconazole prophylaxis).
Telling the Fungi Apart on the Biopsy
The topic insists tissue biopsy and histology are the diagnostic gold standard and scatters each fungus's morphology across the microbiology tabs, but never assembles the identification key the biopsy actually delivers.
- Yeasts (round or oval cells): Candida = budding yeast plus pseudohyphae; Cryptococcus = narrow-based budding yeast with a thick capsule (mucicarmine-positive, clear halo); Blastomyces = broad-based budding yeast; Histoplasma = small intracellular yeast within macrophages; Sporothrix = cigar-shaped yeast.
- Moulds (hyphae): Aspergillus = narrow, septate hyphae with acute-angle branching; Mucorales = broad, aseptate, ribbon-like hyphae with wide-angle branching. This septate-versus-aseptate distinction directs very different therapy (voriconazole versus amphotericin).
- The dimorphic exception: Coccidioides in tissue forms large spherules packed with endospores - neither a yeast nor a hypha - which is pathognomonic. GMS and PAS stain all fungal walls; add mucicarmine for the cryptococcal capsule.
Q: On the essential bone biopsy, how do you tell the fungi apart histologically?
A: Yeasts - Candida (budding yeast + pseudohyphae), Cryptococcus (narrow-based bud + thick capsule, mucicarmine-positive), Blastomyces (broad-based bud), Histoplasma (small intracellular yeast in macrophages), Sporothrix (cigar-shaped). Moulds (hyphae) - Aspergillus (narrow septate, acute-angle branching) vs Mucorales (broad aseptate ribbon-like, wide-angle branching) - a distinction that dictates voriconazole vs amphotericin. Dimorphic exception - Coccidioides forms large spherules packed with endospores (pathognomonic). GMS + PAS stain all fungal walls; mucicarmine for the cryptococcal capsule.
Guidelines, Registries & Global Practice
Global Epidemiology
Fungal osteomyelitis accounts for under 1% of all osteomyelitis but is rising worldwide with expanding immunocompromised populations and global travel. Geography drives the organism:
- Candida - the leading fungal cause globally; linked to candidaemia, central venous catheters, parenteral nutrition, and injecting drug use.
- Aspergillus - worldwide environmental mould; bone disease clusters in haematology/transplant centres but also occurs after trauma or surgery in immunocompetent hosts.
- Endemic mycoses are geographically anchored: Coccidioides (southwestern USA, Mexico, parts of Central/South America), Blastomyces and Histoplasma (Mississippi/Ohio River valleys, Great Lakes, and focally in Africa/Asia), Talaromyces marneffei (Southeast Asia in advanced HIV).
- Cryptococcus gattii - historically associated with tropical/subtropical regions and eucalyptus, with well-described endemicity in Australia and a notable Pacific Northwest (Vancouver Island) outbreak; unlike C. neoformans it can affect immunocompetent hosts and occasionally causes lytic bone lesions mimicking tumour.
Most fungal osteomyelitis affects immunocompromised hosts, but Cryptococcus gattii can cause osteomyelitis in immunocompetent patients. In any patient from an endemic region (including Australia, the Pacific Northwest, or tropical Asia) presenting with a lytic bone lesion mimicking tumour, keep cryptococcal infection in the differential and obtain tissue.
Major Guidelines Side by Side
- First-Line
- Voriconazole
- Key Recommendation
- Voriconazole primary; isavuconazole or liposomal AmB alternatives; TDM advised; surgery for osteomyelitis
- First-Line
- Voriconazole or isavuconazole
- Key Recommendation
- Concordant with IDSA; strong emphasis on TDM and reversal of immunosuppression
- First-Line
- Fluconazole or echinocandin step-down
- Key Recommendation
- 6-12 months therapy; surgical debridement for extensive disease; remove infected hardware
- First-Line
- Fluconazole 400-800mg/day
- Key Recommendation
- Bone/joint disease 12+ months; surgery for abscess/instability; travel history is key
- First-Line
- AmB + flucytosine induction, fluconazole consolidation
- Key Recommendation
- Long-course azole; secondary prophylaxis in HIV until immune reconstitution
Registry & Surveillance Notes
- No arthroplasty-style registry captures fungal osteomyelitis; the evidence base is pooled international case reviews (e.g. the International Osteoarticular Mycoses Study Consortium series for Candida and Aspergillus).
- National antifungal-resistance surveillance (e.g. CDC, ECDC/EUCAST, and the WHO Fungal Priority Pathogens List, 2022) increasingly tracks azole-resistant A. fumigatus and emerging multidrug-resistant Candida (incl. C. auris) - relevant when empirical azole therapy fails.
High- vs Limited-Resource Practice Variation
- Species identification, susceptibility testing, and PCR widely available
- Therapeutic drug monitoring for voriconazole/posaconazole routine
- Newer agents (isavuconazole, liposomal AmB, echinocandins) accessible
- Image-guided biopsy and MRI standard
- Reliance on histopathology (GMS/PAS) and clinical/travel history
- Fluconazole and amphotericin B deoxycholate are mainstays; deoxycholate AmB toxicity a major issue
- Limited TDM and susceptibility testing
- Endemic mycoses and HIV-associated fungal disease carry higher burden
Across all settings, involve infectious diseases early for organism-directed therapy, duration, and management of drug interactions and toxicity.
Controversies & Areas of Uncertainty
"6-12 months" is convention, not RCT-proven. With complete-response rates around 32% and relapse in roughly a third of responders (Gamaletsou Candida series), the true minimum effective duration - and when to stop in immunocompromised hosts - remains undefined.
Surgery clearly reduces relapse in Aspergillus and improves response in mould infection, but the threshold for debridement in indolent Candida or endemic-mycosis bone disease is not standardised, and selection bias clouds the observational data.
Beta-D-glucan and galactomannan are validated for invasive fungal disease broadly, not for osteomyelitis specifically. Their performance for diagnosing or monitoring bone infection (and whether falling levels reliably signal cure) is unproven.
Azole-resistant Aspergillus fumigatus and multidrug-resistant Candida (including C. auris) challenge the "fluconazole/voriconazole first" paradigm. How best to empirically cover resistant organisms in culture-negative bone disease is an open question.
Exam Viva Scenarios
Practise clinical reasoning and management decisions out loud
“A 35-year-old IV drug user presents with 3 months of progressive lower back pain. MRI shows L2-L3 vertebral osteomyelitis with disc involvement. Blood cultures are negative. He has been on empirical flucloxacillin for 4 weeks with no improvement. What is your differential diagnosis and management plan?”
“A 55-year-old woman 6 weeks post-allogeneic stem cell transplant for AML presents with worsening left shoulder pain and fever. She is on immunosuppression and has been neutropenic. CT shows aggressive destruction of the proximal humerus with soft tissue extension. What organism do you suspect and how would you manage this?”
“A 40-year-old man presents with 4 months of left knee pain. He returned from a 6-month work assignment in Arizona, USA 3 months ago. Imaging shows a lytic lesion in the distal femur. Biopsy shows granulomatous inflammation. What is your diagnosis and management?”
Key Organisms
- Candida = MOST COMMON fungal osteomyelitis overall
- Aspergillus = immunocompromised, aggressive, high mortality
- Coccidioides = SW USA endemic, soil exposure
- Cryptococcus gattii = endemic regions, can affect IMMUNOCOMPETENT
Risk Factors (CANDID HOST)
- Chemotherapy, AIDS/HIV, Neutropenia
- Diabetes, IV drug use, Dialysis/central lines
- Transplant, Oral steroids, Soil exposure, TPN
Diagnosis
- TISSUE BIOPSY is ESSENTIAL - blood cultures often negative
- GMS and PAS stains for fungi
- Fungal culture takes 4-6 weeks
- 1,3-beta-D-glucan = nonspecific, supports diagnosis
- Galactomannan = more specific for Aspergillus
Treatment
- Fluconazole = Candida, Cryptococcus, Coccidioides
- Voriconazole = Aspergillus (first-line)
- Itraconazole = Blastomycosis, Histoplasmosis
- Duration 6-12 MONTHS (much longer than bacterial)
- Surgical debridement often required
Key Exam Points
- INDOLENT course - delayed diagnosis is common
- Think fungal if: culture-negative, not responding to antibiotics
- Aspergillus = ALWAYS needs surgery, high mortality
- Travel history for endemic mycoses is crucial
Global Practice
- Cryptococcus gattii can affect IMMUNOCOMPETENT hosts in endemic regions
- Endemic mycoses are geographically anchored - take a travel history
- Voriconazole + surgery is guideline standard for Aspergillus (IDSA/ESCMID)
- Watch for azole-resistant A. fumigatus and C. auris when empirical azoles fail
Evidence Base
Candida Osteomyelitis: Landmark Analysis of 207 Cases
- Review of 207 evaluable cases (1970-2011); median age 30 years, male:female greater than 2:1
- 90% of patients were NOT neutropenic - immunocompetence does not exclude Candida bone disease
- Hematogenous mechanism in 67%, direct inoculation 25%, contiguous 9%
- Adults: vertebrae most common; children: femur most common; non-albicans species 35%
- Combined surgery plus antifungal in 48%; complete response only 32%; relapse in 32% of responders
Aspergillus Osteomyelitis: Surgery Reduces Relapse
- Review of 180 evaluable protocol-defined cases of Aspergillus osteomyelitis
- Most common sites: vertebrae 46%, cranium 23%, ribs 16%, long bones 13%
- Affected immunocompromised AND immunocompetent hosts (41% had prior fracture, trauma, or surgery)
- Overall mortality 25%; vertebral disease complicated by cord compression in 47%
- Surgery plus antifungal therapy had far fewer relapses than antifungals alone (8% vs 30%, P = 0.006)
IDSA Guideline: Coccidioidomycosis (incl. Bone & Joint)
- 2016 IDSA clinical practice guideline spanning the full spectrum of coccidioidomycosis
- Residence in or travel to endemic areas is the critical element for recognition
- Bone and joint disease requires prolonged oral azole therapy (typically 12+ months)
- Surgical debridement indicated for abscess, bony instability, or failure of medical therapy
- At-risk and immunocompromised patients may need extended or lifelong suppressive therapy
1,3-Beta-D-Glucan for Diagnosis of Invasive Fungal Infection
- Meta-analysis of 16 studies, 2979 patients (594 with proven/probable invasive fungal infection)
- Pooled sensitivity 76.8% and specificity 85.3%; area under summary ROC curve 0.89
- Marked between-study heterogeneity; does not identify specific organism or site
- False positives with haemodialysis, certain antibiotics, and IVIG
- Useful adjunct but does NOT replace tissue diagnosis
Non-Aspergillus Mould Osteoarticular Infection: Combined Medical-Surgical Approach
- Systematic review of 145 osteoarticular infections from non-Aspergillus filamentous fungi (1970-2013)
- 62% immunocompromised; direct inoculation in 54.5% (trauma/puncture in children, prior surgery in adults)
- Scedosporium apiospermum (33%) and Lomentospora prolificans (16%) were the leading moulds
- Combined antifungal therapy plus surgery used in 69%, with overall response in 85.8%
- Single-agent voriconazole achieved response in 94.1% of hyalo-/phaeohyphomycosis cases
IDSA Guideline: Diagnosis & Management of Aspergillosis
- 2016 IDSA practice guideline for the diagnosis and management of aspergillosis
- Voriconazole recommended as primary therapy for invasive aspergillosis, including osteomyelitis
- Isavuconazole and liposomal amphotericin B are recommended alternatives
- Therapeutic drug monitoring of voriconazole advised given variable pharmacokinetics
- Surgery recommended for Aspergillus osteomyelitis and discitis alongside antifungal therapy